Precision Neuroscience receives FDA 510(k) clearance for Layer 7 — first regulatory clearance for next-gen wireless BCI
Summary
Precision Neuroscience received FDA 510(k) clearance for the Layer 7 Cortical Interface in April 2025, authorizing commercial use for recording, monitoring, and stimulating electrical activity on the brain surface for up to 30 days. The clearance marks the first full regulatory clearance granted to any company developing a next-generation wireless brain-computer interface — a landmark FDA milestone for the BCI field that validates the thin-film electrode approach.
Why it matters
FDA 510(k) clearance for a next-gen wireless cortical BCI electrode array is the most significant BCI regulatory milestone since BrainGate's early feasibility approvals. Precision's 30-day intraoperative use pathway creates immediate commercial revenue while their chronic implant program develops — a dual-track strategy that generates real-world clinical data and hospital relationships simultaneously.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial